ES2129078T3 - Preparacion farmaceutica que comprende un compuesto capaz de degradar los antibioticos beta-lactamicos y su utilizacion. - Google Patents

Preparacion farmaceutica que comprende un compuesto capaz de degradar los antibioticos beta-lactamicos y su utilizacion.

Info

Publication number
ES2129078T3
ES2129078T3 ES93902271T ES93902271T ES2129078T3 ES 2129078 T3 ES2129078 T3 ES 2129078T3 ES 93902271 T ES93902271 T ES 93902271T ES 93902271 T ES93902271 T ES 93902271T ES 2129078 T3 ES2129078 T3 ES 2129078T3
Authority
ES
Spain
Prior art keywords
pharmaceutical preparation
beta
compound capable
antibiotics
degrading beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93902271T
Other languages
English (en)
Inventor
Pekka Untamo Heino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remedy Consulting Oy
Original Assignee
Remedy Consulting Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedy Consulting Oy filed Critical Remedy Consulting Oy
Application granted granted Critical
Publication of ES2129078T3 publication Critical patent/ES2129078T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01004—Amidase (3.5.1.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02006—Beta-lactamase (3.5.2.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A UN USO SANITARIO, UN METODO SANITARIO Y UNA PREPARACION FARMACEUTICA. LA INVENCION PERMITE QUE LA ACCION DE ANTIBIOTICOS (BETA)-LACTAMA SE DIRIJA Y SUS EFECTOS LATERALES SE REDUZCAN POR LA INACTIVACION DE PARTE DEL ANTIBIOTICO EN UN SECTOR DESEADO DEL TRACTO DIGESTIVO DISTAL DEL ESTOMAGO ADMINISTRANDO, SEPARADAMENTE DESDE O SIMULTANEAMENTE CON EL ANTIBIOTICO, UNA ENZIMA, COMO (BETA)-LACTAMASA, LA CUAL ROMPE LA RESISTENCIA DE DICHO ANTIBIOTICO.
ES93902271T 1992-01-17 1993-01-18 Preparacion farmaceutica que comprende un compuesto capaz de degradar los antibioticos beta-lactamicos y su utilizacion. Expired - Lifetime ES2129078T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI920206A FI920206A0 (fi) 1992-01-17 1992-01-17 Medicinsk anvaendning, medicinskt foerfarande och preparat.

Publications (1)

Publication Number Publication Date
ES2129078T3 true ES2129078T3 (es) 1999-06-01

Family

ID=8534042

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93902271T Expired - Lifetime ES2129078T3 (es) 1992-01-17 1993-01-18 Preparacion farmaceutica que comprende un compuesto capaz de degradar los antibioticos beta-lactamicos y su utilizacion.

Country Status (9)

Country Link
US (1) US5607671A (es)
EP (1) EP0671942B1 (es)
AT (1) ATE174513T1 (es)
DE (1) DE69322659T2 (es)
DK (1) DK0671942T3 (es)
ES (1) ES2129078T3 (es)
FI (1) FI920206A0 (es)
GR (1) GR3029699T3 (es)
WO (1) WO1993013795A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2173147C2 (ru) * 1996-05-09 2001-09-10 Санкио Компани Лимитед Применение производных 1-метилкарбопенема, антибактериальная в отношении helicobacter pylori композиция, содержащая в качестве активного ингредиента 1-метилкарбопенемовые производные и способ профилактики или лечения инфекционных заболеваний
GB2318732A (en) 1996-11-01 1998-05-06 Johnson & Johnson Medical Wound healing compositions containing alpha-1-antitrypsin
FI109970B (fi) * 2002-02-20 2002-11-15 Remedal Oy Valmiste ja menetelmä painon pudottamiseksi
FR2843301B1 (fr) * 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
FR2843302B1 (fr) * 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
US7387793B2 (en) * 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20080317666A1 (en) * 2005-02-09 2008-12-25 Elias Fattal Colonic Delivery of Active Agents
FI119190B (fi) 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
US8273376B2 (en) * 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
US20080124279A1 (en) * 2006-11-17 2008-05-29 Antoine Andremont Colonic delivery using Zn/pectin beads with a Eudragit coating
EP2162119A2 (en) * 2007-05-21 2010-03-17 Phenomix Corporation Stable pharmaceutical formulation for a dpp-iv inhibitor
ITBO20080297A1 (it) * 2008-05-16 2009-11-17 Archimede R & D S R L Composizione enzimatica per ridurre il rilascio di principi attivi farmaceutici nell'ambiente.
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
ITMI20121715A1 (it) * 2012-10-11 2014-04-12 Bioikos Ambiente S R L Composizioni farmaceutiche con ridotto impatto ambientale
WO2015161243A2 (en) 2014-04-17 2015-10-22 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
EP3186379B1 (en) 2014-08-28 2020-04-08 Synthetic Biologics, Inc. E. coli-based production of beta-lactamase
MX2017004473A (es) 2014-10-08 2017-10-12 Synthetic Biologics Inc Formulaciones de betalactamasa y usos de las mismas.
FR3027307B1 (fr) * 2014-10-16 2016-11-04 Azurrx Sas Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
WO2016105498A1 (en) 2014-12-23 2016-06-30 Synthetic Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
WO2016137993A1 (en) 2015-02-23 2016-09-01 Synthetic Biologics, Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
US10709773B2 (en) 2015-03-06 2020-07-14 Synthetic Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
CN108699545A (zh) 2016-02-23 2018-10-23 达·沃尔泰拉公司 β-内酰胺酶变体
US10988749B2 (en) 2016-02-23 2021-04-27 Da Volterra Beta-lactamase variants
MX2020004319A (es) 2017-10-25 2020-10-12 Da Volterra Variantes de beta-lactamasas.
EP3965804B1 (en) * 2019-05-06 2025-04-02 Theriva Biologics, Inc. Beta-lactamase compositions for treatment of graft versus host disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2613624B1 (fr) * 1987-04-10 1990-11-23 Roussy Inst Gustave Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
CS275231B2 (en) * 1989-09-29 1992-02-19 Ustav Makormolekularni Chemie Medicine bottle

Also Published As

Publication number Publication date
DE69322659T2 (de) 2000-01-05
US5607671A (en) 1997-03-04
DK0671942T3 (da) 1999-08-23
EP0671942B1 (en) 1998-12-16
GR3029699T3 (en) 1999-06-30
DE69322659D1 (de) 1999-01-28
FI920206A0 (fi) 1992-01-17
ATE174513T1 (de) 1999-01-15
EP0671942A1 (en) 1995-09-20
WO1993013795A1 (en) 1993-07-22

Similar Documents

Publication Publication Date Title
ES2129078T3 (es) Preparacion farmaceutica que comprende un compuesto capaz de degradar los antibioticos beta-lactamicos y su utilizacion.
ES2081531T3 (es) Composiciones farmaceuticas que contienen rifaximina para el tratamiento de infecciones vaginales.
ES2083668T3 (es) Combinaciones antiviricas que contienen analogos de nucleosidos.
ES2172303T3 (es) Agentes terapeuticos obtenidos por catalisis enzimatica.
DK0466913T3 (da) Tilslutningsadaptor til katetre
IT8723134A0 (it) Procedimento per la fabbricazione di dispositivi integrati cmos con lunghezze di porta ridotte.
ECSP045104A (es) Ligandos de los receptores de los cannabinoides
ID22994A (id) Senyawa aminoalkil glikosamina fosfat dan penggunaannya sebagai adjuvan dan pemicu kekebalan
CO4940450A1 (es) Formulaciones farmaceuticas que contienen voriconazol
BR9810495A (pt) Composição farmacêutica
HUP9900492A2 (hu) 3,6-Ketál és enol-éter makrolid antibiotikumok és ezeket tartalmazó gyógyszerkészítmények
ES2173391T3 (es) Derivados de 2-aminobenzazepina y su uso para el tratamiento de la inmunodepresion.
PT876388E (pt) Derivados de eritromicina triciclica
DK0930077T3 (da) Cyclodextrinpræparater indeholdende et avermectin- eller milbemycinderivat
AU2005099A (en) Methods and compositions for the treatment and prevention of (staphylococcus aureus) infections
ES2147163A1 (es) Una composicion farmaceutica con actividad reguladora de la expresion de las moleculas de adhesion.
AU4445089A (en) Lactamimides in the treatment of drug-resistant protozoal infections
AR030662A1 (es) Beta-tio-alfa-aminoacidos, procedimiento para su fabricacion, medicamentos que contienen estos compuestos y el uso de los tioaminoacidos para la preparacion de medicamentos
ES2145114T3 (es) Combinacion de atovacuona con proguanil para el tratamiento de infecciones protozoarias.
ES2125309T3 (es) Derivados de tiomarinol y procedimientos para su preparacion.
ES2159676T3 (es) Derivados de triazol con actividad antimicotica e intermediarios.
GT199600072A (es) Formas zwitterionicas de trovafloxacina.
NO920050L (no) Trifluormetyl-1-karba(1-detia)cefemer
ES2168240T1 (es) Uso de efectores del sistema nervioso central colinergico para el tratamiento del delirio.
ES2150034T3 (es) Empleo de las 2-aminotetralinas substituidas en 6,7 para la preparacion de composiciones farmaceuticas de utilidad para el tratamiento del choque septico, y composiciones farmaceuticas antipireticas y antiinflamatorias.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 671942

Country of ref document: ES